Zoetis (ZTS) 10-K Summary — Year Ended Dec 31, 2025
Zoetis is a global animal health company. The company reported increased revenue and positive net income and operating cash flow in the latest annual period.
Key takeaway
Year ended Dec 31, 2025 · FY2025 10-K
Zoetis is a global animal health company. The company reported increased revenue and positive net income and operating cash flow in the latest annual period.
Financial snapshot
Selected annual figures reported with the filing, shown separately from the narrative summary.
Annual revenue
$9.5B
Revenue reported for the fiscal year.
Operating income
n/a
Income from operations reported for the year.
Net income
$2.7B
Net income reported for the year.
Operating cash flow
$2.9B
Cash generated by operating activities.
Annual revenue trend
Reported annual revenue and its change from the preceding fiscal year.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2022 | $8.1B | +3.9% |
| Dec 31, 2023 | $8.5B | +5.7% |
| Dec 31, 2024 | $9.3B | +8.3% |
| Dec 31, 2025 | $9.5B | +2.3% |
Business overview
The company operates in the animal health sector, focusing on discovery, development, manufacturing, and commercialization of products. It has multiple operating segments and serves customers globally through its sales and marketing efforts. Research and development is a key component of its business.
Financial performance
Revenue increased compared to the prior year. Net income and operating cash flow were positive for the period.
Material risks
The filing includes a risk factors section, but the supplied context does not provide details of specific risks. Therefore, no specific risks can be identified from the available information.
Liquidity and capital
Inventories increased to support forecasted demand, and property, plant, and equipment expanded due to capital spending. Accounts receivable also rose with higher sales.
What to watch
The trajectory of revenue growth as reported in the next filing.